Trials / Completed
CompletedNCT01786135
A Safety Study of SGN-CD19A for B-Cell Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Seagen Inc. · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (B-NHL)
Conditions
- Burkitt Lymphoma
- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Mantle-Cell
- Precursor B-cell Lymphoblastic Leukemia-Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SGN-CD19A | SGN-CD19A (IV) once every 21 days (3 weeks) or 42 days (6 weeks) |
Timeline
- Start date
- 2013-02-01
- Primary completion
- 2015-08-01
- Completion
- 2017-02-16
- First posted
- 2013-02-07
- Last updated
- 2017-10-19
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01786135. Inclusion in this directory is not an endorsement.